Matches in Wikidata for { <http://www.wikidata.org/entity/Q95565083> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- Q95565083 description "artículu científicu" @default.
- Q95565083 description "wetenschappelijk artikel" @default.
- Q95565083 description "наукова стаття" @default.
- Q95565083 name "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study" @default.
- Q95565083 name "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study" @default.
- Q95565083 type Item @default.
- Q95565083 label "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study" @default.
- Q95565083 label "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study" @default.
- Q95565083 prefLabel "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study" @default.
- Q95565083 prefLabel "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study" @default.
- Q95565083 P1433 Q95565083-E68ED2DC-B55E-4877-BC9C-68AF1528DE6E @default.
- Q95565083 P1476 Q95565083-BDB23F5D-B83C-40F3-8AC8-A93BFFE88888 @default.
- Q95565083 P2093 Q95565083-13DB4762-77AB-4812-9C04-6495F3CF6CBE @default.
- Q95565083 P2093 Q95565083-1C6776F6-2D7B-4BD4-BAEF-AB8A680C28E3 @default.
- Q95565083 P2093 Q95565083-5014CE65-1729-41D0-8201-175EDFFA9CE4 @default.
- Q95565083 P2093 Q95565083-50BB0425-6488-4772-BE9F-4A4B0D8F1ED4 @default.
- Q95565083 P2093 Q95565083-664CA54F-4844-4CCD-B1F1-6570F9484FF4 @default.
- Q95565083 P2093 Q95565083-680B59DA-A8DC-4653-BE58-A0A55B38B669 @default.
- Q95565083 P2093 Q95565083-6CF42A65-432A-4CD9-B049-9613125627E4 @default.
- Q95565083 P2093 Q95565083-7B427108-0343-4CCF-B4E4-060273B52A86 @default.
- Q95565083 P2093 Q95565083-9A994113-22B5-4465-9FF6-20BC0737F2BC @default.
- Q95565083 P2093 Q95565083-C2B3CF80-19A7-4710-9D71-AA9FFE1DE0AC @default.
- Q95565083 P2093 Q95565083-CBE9BB94-6E6D-4C87-B85B-5DEA07483EC5 @default.
- Q95565083 P2093 Q95565083-D1BFC047-309E-4B8B-8F07-C8AF77A7A188 @default.
- Q95565083 P2093 Q95565083-DB89630F-202F-4A5E-AA30-F3300D1D9171 @default.
- Q95565083 P2093 Q95565083-E4E2D34C-9A42-4EED-BA06-115A08B60853 @default.
- Q95565083 P2093 Q95565083-F12E3134-6D32-428E-A26B-D66BF402D365 @default.
- Q95565083 P2093 Q95565083-F9812866-7D08-4D3C-8EBF-A72827946C39 @default.
- Q95565083 P304 Q95565083-38E79AB8-4104-4B65-97D6-996B9DA31777 @default.
- Q95565083 P31 Q95565083-053C204F-20CD-492A-A1A6-75506D3519DA @default.
- Q95565083 P356 Q95565083-CDFBFCE2-D1AC-4396-B41F-FF3C14D04A31 @default.
- Q95565083 P433 Q95565083-DD884BB5-19F3-42A8-B94A-A20A5B050EFA @default.
- Q95565083 P478 Q95565083-DC2D53D1-C132-440B-9A73-4B74C07B8463 @default.
- Q95565083 P50 Q95565083-3DFB4A5A-43A8-43EB-8D06-48022BCA90DB @default.
- Q95565083 P50 Q95565083-69B6116F-6D30-4130-9225-31BF15156CF0 @default.
- Q95565083 P50 Q95565083-9C908034-9446-40AC-A23F-5D7CFC278409 @default.
- Q95565083 P577 Q95565083-95F0DB49-EFB0-4697-AFF2-2B91616EEB39 @default.
- Q95565083 P698 Q95565083-46C99587-368B-465B-989E-E3649E1E09EA @default.
- Q95565083 P921 Q95565083-97E5869F-9D5A-452C-B61A-7C6756FBEC6B @default.
- Q95565083 P356 DKZ224 @default.
- Q95565083 P698 31269208 @default.
- Q95565083 P1433 Q6294770 @default.
- Q95565083 P1476 "Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study" @default.
- Q95565083 P2093 "Cathia Soulié" @default.
- Q95565083 P2093 "Christine Katlama" @default.
- Q95565083 P2093 "Dominique Costagliola" @default.
- Q95565083 P2093 "Esteban Martinez" @default.
- Q95565083 P2093 "Fanny Cardon" @default.
- Q95565083 P2093 "Gilles Peytavin" @default.
- Q95565083 P2093 "Jacqueline Capeau" @default.
- Q95565083 P2093 "Jacques Reynes" @default.
- Q95565083 P2093 "Lambert Assoumou" @default.
- Q95565083 P2093 "Lydie Béniguel" @default.
- Q95565083 P2093 "Marc-Antoine Valantin" @default.
- Q95565083 P2093 "Olivier Bouchaud" @default.
- Q95565083 P2093 "Sami Kolta" @default.
- Q95565083 P2093 "Severine Gibowski" @default.
- Q95565083 P2093 "Soraya Fellahi" @default.
- Q95565083 P2093 "members of the ANRS 163 ETRAL study" @default.
- Q95565083 P304 "2742-2751" @default.
- Q95565083 P31 Q13442814 @default.
- Q95565083 P356 "10.1093/JAC/DKZ224" @default.
- Q95565083 P433 "9" @default.
- Q95565083 P478 "74" @default.
- Q95565083 P50 Q108298727 @default.
- Q95565083 P50 Q111669983 @default.
- Q95565083 P50 Q41564214 @default.
- Q95565083 P577 "2019-09-01T00:00:00Z" @default.
- Q95565083 P698 "31269208" @default.
- Q95565083 P921 Q421552 @default.